Advanced glycation end products and soluble receptor as markers of oxidative stress in children on hemodialysis

Renal Failure
Gamila S M El-SaeedSafaa M Abdelrahman

Abstract

Advanced glycation end products (AGEs) have biological properties that may contribute to the mortality of children on hemodialysis (HD). This study examines the relationship of LMW fluorescence AGEs, oxidized LDL (ox-LDL), soluble receptor AGE (sRAGE) as markers of oxidative stress in children with end stage renal disease (ESRD) undergoing HD. Thirty children with ESRD undergoing HD, and 30 healthy, age- and sex-matched children were included. Serum levels of LMW fluorescence AGEs, sRAGE, oxidized LDL (ox-LDL), pre- and post-dialysis urea, high-sensitivity C-reactive protein (hs-CRP), hemoglobin (Hb) and serum albumin (ALB), were measured. Abnormal serum inflammatory changes: elevated levels of LMW AGEs, sRAGE, oxLDL, CRP and urea were exhibited in HD children compared with healthy controls; more so in anemic when compared to non-anemic patients. Significant positive correlation was found between serum levels of AGEs and sRAGE. The low molecular weight form of AGEs is associated with oxidative stress in children receiving chronic HD, and may be important in the mechanisms leading to atherosclerosis and inflammation in such patients. LMW AGEs levels showed a negative correlation with sRAGE and both exhibit a significant negative...Continue Reading

References

Oct 1, 1984·Annals of Internal Medicine·M BrownleeA Cerami
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·R BucalaH Vlassara
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·T KoschinskyH Vlassara
Feb 13, 1999·Kidney International·J ZimmermannC Wanner
Jun 14, 2000·Annals of Medicine·T W Du Clos
Jul 18, 2001·The Journal of Clinical Investigation·Y YamamotoH Yamamoto
Jun 26, 2002·Kidney International·Susanne B SchwedlerChristoph Wanner
Feb 22, 2003·Journal of the American Society of Nephrology : JASN·Jaime UribarriHelen Vlassara
Mar 4, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Günter SteinSybille Franke
Mar 29, 2003·Diabetes Care·Merlin C ThomasGeorge Jerums
May 23, 2003·Journal of the American Society of Nephrology : JASN·Mohammed E SulimanPeter Stenvinkel
Aug 26, 2004·Kidney International·Merlin C ThomasGeorge Jerums
Oct 19, 2004·Seminars in Nephrology·Nosratola D Vaziri
Feb 26, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Colomba FalconeDiego Geroldi
Jun 3, 2005·Journal of the American Society of Nephrology : JASN·Josephine M ForbesMark E Cooper
Jul 20, 2005·Current Drug Targets·M C ThomasM E Cooper
Jul 23, 2005·Annals of the New York Academy of Sciences·Akihiko SaitoFumitake Gejyo
Jul 23, 2005·Annals of the New York Academy of Sciences·Merlin C ThomasMark E Cooper
Nov 12, 2005·European Journal of Clinical Investigation·I C Macdougall, A C Cooper
Feb 24, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Marta KalousováTomás Zima
Mar 3, 2006·Nephrology·Peter Stenvinkel
Mar 8, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthew A RobertsFrancesco L Ierino
Jan 11, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Peter StenvinkelZiad Massy
Nov 27, 2008·Kidney International. Supplement·Victoria CachofeiroJosé Luño
Mar 12, 2009·Clinical Science·Anastasia Z KaleaBarry I Hudson
Jun 8, 2012·Clinical and Investigative Medicine. Médecine Clinique Et Experimentale·Abdolkarim MahroozGhorban Gohari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.